Infuence Of 2-Weeks Ingestion Of High Chlorogenic Acid Coffee On Mood State, Performance, And Postexercise Inflammation And Oxidative Stress: A Randomized, Placebo-Controlled Trial by NC DOCKS at Appalachian State University & Nieman, David
Archived version from NCDOCKS Institutional Repository http://libres.uncg.edu/ir/asu/ 
Influence Of 2-Weeks Ingestion Of High Chlorogenic 
Acid Coffee On Mood State, Performance, And 
Postexercise Inflammation And Oxidative Stress:
 A Randomized, Placebo-Controlled Trial
By: David C. Nieman, Courtney L. Goodman, Christopher R. Capps,
 Zack L. Shue, and Robert Arnot
Abstract
This study measured the influence of 2-weeks ingestion of high chlorogenic acid (CQA) coffee on postexercise 
inflammation and oxidative stress, with secondary outcomes including performance and mood state. Cyclists (N 
= 15) were randomized to CQA coffee or placebo (300 ml/day) for 2 weeks, participated in a 50-km cycling time 
trial, and then crossed over to the opposite condition with a 2-week washout period. Blood samples were 
collected pre- and postsupplementation, and immediately postexercise. CQA coffee was prepared using the 
Turkish method with 30 g lightly roasted, highly ground Hambela coffee beans in 300 ml boiling water, and 
provided 1,066 mg CQA and 474 mg caffeine versus 187 mg CQA and 33 mg caffeine for placebo. Plasma 
caffeine was higher with CQA coffee versus placebo after 2-weeks (3.3-fold) and postexercise (21.0-fold) 
(interaction effect, p < .001). Higher ferric reducing ability of plasma (FRAP) levels were measured after exercise 
with CQA coffee versus placebo (p = .01). No differences between CQA coffee and placebo were found for 
postexercise increases in plasma IL-6 (p = .74) and hydroxyoctadecadienoic acids (9 + 13 HODEs) (p = .99). 
Total mood disturbance (TMD) scores were lower with CQA coffee versus placebo (p = .04). 50-km cycling time 
performance and power did not differ between trials, with heart rate and ventilation higher with CQA coffee, 
especially after 30 min. In summary, despite more favorable TMD scores with CQA coffee, these data do not 
support the chronic use of coffee highly concentrated with chlorogenic acids and caffeine in mitigating 
postexercise inflammation or oxidative stress or improving 50-km cycling performance.
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This study measured the influence of 2-weeks ingestion of high chlorogenic acid (CQA) coffee on postexercise
inflammation and oxidative stress, with secondary outcomes including performance and mood state. Cyclists
(N = 15) were randomized to CQA coffee or placebo (300 ml/day) for 2 weeks, participated in a 50-km cycling
time trial, and then crossed over to the opposite condition with a 2-week washout period. Blood samples were
collected pre- and postsupplementation, and immediately postexercise. CQA coffee was prepared using the
Turkish method with 30 g lightly roasted, highly ground Hambela coffee beans in 300 ml boiling water, and
provided 1,066 mg CQA and 474 mg caffeine versus 187 mg CQA and 33 mg caffeine for placebo. Plasma
caffeine was higher with CQA coffee versus placebo after 2-weeks (3.3-fold) and postexercise (21.0-fold)
(interaction effect, p < .001). Higher ferric reducing ability of plasma (FRAP) levels were measured after
exercise with CQA coffee versus placebo (p = .01). No differences between CQA coffee and placebo were
found for postexercise increases in plasma IL-6 (p = .74) and hydroxyoctadecadienoic acids (9 + 13 HODEs)
(p = .99). Total mood disturbance (TMD) scores were lower with CQA coffee versus placebo (p = .04). 50-km
cycling time performance and power did not differ between trials, with heart rate and ventilation higher with
CQA coffee, especially after 30 min. In summary, despite more favorable TMD scores with CQA coffee, these
data do not support the chronic use of coffee highly concentrated with chlorogenic acids and caffeine in
mitigating postexercise inflammation or oxidative stress or improving 50-km cycling performance.
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Coffee is one of the most commonly consumed
beverages worldwide, and is the primary dietary source
for polyphenols in most European regions (Zamora-Ros
et al., 2016). In the United States, coffee is consumed by
75% of the adult population (mean intake, 417 ml/d),
with 49% reporting daily intake (Loftfield et al., 2016).
Coffee is a good source of caffeine and chlorogenic
acids (CQA), a group of nonflavonoid polyphenol com-
pounds comprising hydroxycinnamates linked to quinic
acid that form caffeoylquinic acids (CQA), feruloylqui-
nic acids (FQA), and p-coumaroylquinic acids
(p-CoQA) (Del Rio et al., 2010; Tajik et al., 2017).
Coffee contains many isomers of these compounds, with
the principal CQA in coffee being 5-caffeoylquinic acid
(5-CQA) (Monteiro et al., 2007). A typical cup of coffee
delivers 15 to 325 mg CQAs (Richelle et al., 2001), and
heavy coffee consumers may take in up to 1,000 mg
CQA per day, depending on multiple factors including
the specific coffee variety, the geographic location where
it is grown, and the processes used in postharvest,
washing/drying procedures, and roasting and grinding
particle size of the coffee beans (Lang et al., 2013; Liang
& Kitts, 2014, 2015; Ludwig et al., 2014).
Coffee consumption has been associated with mul-
tiple health benefits and reduced total mortality rates
(Ding et al., 2015; Je & Giovannucci, 2014), and these
have been primarily attributed to CQA antioxidant, anti-
inflammatory, and blood vessel dilation effects (Kempf
et al., 2010; Liang & Kitts, 2015; Lopez-Garcia et al.,
2006; Tajik et al., 2017). In vitro indicate that CQAs
have antioxidant and anti-inflammatory activity,
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alleviate oxidative stress and inflammation in various
animal disease models, and reduce related biomarkers in
human clinical trials (Tajik et al., 2017). Acute coffee
ingestion has been linked to a modest and transient
increase in plasma antioxidant activity (Agudelo-
Ochoa et al., 2016; Moura-Nunes et al., 2009; Natella
et al., 2002). Limited data suggest that CQAs may
improve mood state, but to a lesser extent than caffeine
(Camfield et al., 2013).
CQAs are poorly and incompletely absorbed in the
upper gastrointestinal tract, with most entering the large
intestine unmetabolized (Farah et al., 2008; Monteiro
et al., 2007; Renouf et al., 2014; Stalmach et al., 2010).
CQAs are metabolized by colon bacteria, with cleavage
of the ester link between quinic acid and caffeic acid.
Caffeic acid may be absorbed through the colon back
into the body, with conjugation into O-methylated,
sulphated and glucuronidated derivatives, and transfor-
mation into dihydro metabolites such as dihydrocaffeic
acid and dihydroferulic acid (Ludwig et al., 2014). CQA
metabolites absorbed through the small intestine are
conjugated and have an early appearance in the plasma
at low concentrations (∼1–2 hours), with CQA metabo-
lites formed by intestinal microflora appearing late
(>6 hours) at high concentrations and persisting in the
plasma, but with wide variation between individuals
(Lang et al., 2013; Renouf et al., 2014). CQAs act as
prebiotics in the colon due to the selective metabolism
and expansion of specific bacterial populations related to
human health (Mills et al., 2015).
Caffeine in moderate to high doses (3–13 mg/kg
body mass) ingested prior to and during prolonged,
intensive exercise has been linked in many studies to
improved performance and decreased ratings of per-
ceived exertion (Doherty & Smith, 2005; Ganio et al.,
2009; Goldstein et al., 2010; McLellan et al., 2016;
Spriet, 2014; Tarnopolsky, 2008). The principal mecha-
nism of caffeine’s ergogenic effects is through its ability
to act as an adenosine receptor antagonist to induce
effects on the central and peripheral nervous system to
reduce pain and exertion perception, improve motor
recruitment, and excitation-contraction coupling
(Tarnopolsky, 2008). Although most studies have
used anhydrous caffeine, moderate but inconsistent evi-
dence supports the use of coffee as an ergogenic aid to
improve performance in endurance cycling and running
(Church et al., 2015; Goldstein et al., 2010; Hodgson
et al., 2013).
Given the bioactive effects of CQAs and caffeine,
we hypothesized that 2-weeks chronic ingestion of
caffeinated coffee high in CQAs (including the morning
of the exercise challenge bout) would mitigate exercise-
induced inflammation and oxidative stress while sup-
porting endurance performance. The primary purpose of
this study was to investigate the influence of 2-weeks
ingestion of high CQA coffee on postexercise (50-km
cycling time trial) inflammation and oxidative stress,
with secondary outcomes including performance and
mood state.
Methods
Participants
The research procedures were conducted at the Human
Performance Laboratory operated by Appalachian
State University at the North Carolina Research Cam-
pus (NCRC) in Kannapolis, NC. Male (n = 10) and
female (n = 5) cyclists ages 19 to 51 years were re-
cruited that were healthy, non-smokers, habitually
consumed less than 3 cups of coffee per day during
the previous month, did not regularly consume tablets
containing caffeine or high amounts of energy drinks or
other beverages containing caffeine, regularly com-
peted in road races (category 1 to 5), and were capable
of cycling 75 km in a laboratory setting. Study parti-
cipants agreed to train normally, maintain weight, and
avoid the regular use of large-dose vitamin and mineral
supplements, herbs, and medications that had the
potential to influence inflammation and immune func-
tion for the duration of the study. Participants signed
informed consent, and study procedures were approved
by the Institutional Review Board at Appalachian State
University.
Research Design
This study used a double-blind, placebo-controlled,
randomized crossover design. Study participants (N = 15)
were randomized to coffee or placebo conditions for two
weeks, participated in a 50-km cycling time trial, and then
crossed over to the opposite condition after a 2-week
washout period. Participants completed the two arms of
the study, and data were analyzed using repeated mea-
sures analysis of variance (ANOVA), with participants
operating as their own controls.
One to two weeks prior to the first 50-km cycling
time trial, participants reported to the NCRC Human
Performance Lab for orientation/baseline testing. Parti-
cipants were screened for inclusion and exclusion crite-
ria, and provided voluntary consent. Demographic and
training histories were acquired with questionnaires.
Maximal power, oxygen consumption, ventilation,
and heart rate were measured during a graded exercise
test (25 W increase every 2 min, starting at 150 W) with
the Cosmed Quark CPET metabolic cart (Rome, Italy)
and the Lode cycle ergometer (Lode Excaliber Sport,
Lode B.V., Groningen, Netherlands). Body composition
was measured with the Bod Pod body composition
analyzer (Cosmed, Rome, Italy).
Study participants were randomized to ingest one cup
per day of high chlorogenic coffee (CQA coffee) or
placebo for two weeks using double-blind procedures.
Following the 2-week supplementation period, cyclists
participated in a 50-km cycling time trial using their
bicycles on CompuTrainer devices. Blood samples were
collected pre– and post–2-weeks supplementation, and
immediately following the 50-km cycling time trial.
Cyclists crossed over to the opposite beverage, and repeated
all procedures following a 2-week washout period.
Participants returned to the lab within one to two
weeks after baseline testing in an overnight fasted state
to provide a blood sample. Participants received a
2-week supply of high CQA coffee or placebo coffee
with written and video instructions to prepare using
Turkish methods, and ingested 1 cup per day.
During the 3-day period prior to each 50-km cycling
trial, participants tapered exercise training (as if preparing
for a race) and ingested a moderate-carbohydrate diet
using a food list restricting high fat foods and visible fats.
Participants were instructed to keep the food record
current by listing items immediately after theywere eaten,
to measure and record the volume using household
measures (tablespoons, cups, slices, ounces), to provide
sufficient detail about the method of preparation and
include condiments, sugar, oils, butter, and other visible
fats, and to avoid the tendency to eat less or under-report
because of the recording process. The 3-day food records
were analyzed for nutrient and flavonoid content using
the Food Processor v. 11.1 (ESHAResearch, Salem, OR).
ESHA’s port utility (v. 4.0) was used to upload the
Flavonoid Values for USDA Survey Foods and Bev-
erages (FNDDS) 2007–2010 database (Sebastian et al.,
2016), and each food/beverage was assessed for macro-
and micro-nutrients, and total flavonoids.
For each trial, participants came to the lab at 7:00 am
in an overnight fasted state (at least 9 h with no food or
beverage other than water) and completed the 50-cycling
time trials. Participants first provided a blood sample,
and then according to the randomized schedule ingested
either one cup of hot CQA coffee or placebo. At
approximately 7:30 am, participants started the 50-km
cycling time trial. Participants used their own bicycles on
CompuTrainer Pro Model 8001 trainers (RacerMate,
Seattle, WA), with a flat 50-km course controlled by
the CompuTrainer MultiRider software system (Racer-
Mate, Seattle, WA). Heart rate and rating of perceived
exertion (RPE) were recorded every 30 minutes, and
workload (watts) continuously monitored. Oxygen con-
sumption, carbon dioxide production, and ventilation
were measured using the Cosmed CPET metabolic
system every 30 minutes. Participants consumed water
ad libitum, but did not exceed 3 ml/kg per 15 minutes,
and no other food or beverages were ingested during the
50-km cycling time trials. A blood sample was collected
immediately postexercise. Plasma was aliquoted and
flash-frozen in liquid nitrogen, and stored at −80°C
before analysis.
High-Chlorogenic Acid Coffee and Placebo
Lightly roasted coffee beans high in chlorogenic acids
(CQA coffee) were selected from the Hambela Estate in
Ethiopia and ground to a very small particle size. Study
participants were instructed to use the Turkish method of
preparation, and consume one 300 ml cup of coffee each
morning for two weeks. Participants measured 30 grams
of coffee grounds using a drip scale, and then transferred
the coffee and 300 ml water into a Turkish copper coffee
pot (supplies, written instructions, and video were pro-
vided for each study participant). With the stove top
burner on, the coffee and water were stirred periodically
until boiling occurred. The heat was turned off after three
minutes of boiling, with care to avoid the coffee foaming
over the top. The coffee grounds were allowed to settle for
one to two minutes, with the coffee supernatant poured
into a cup and then consumed black (without milk, cream
or similar products). High Performance Liquid Chroma-
tography (HPLC) analysis of the Turkish brewed coffee
(30 grams in 300 ml boiled water) was conducted by the
GreenMountain Laboratories, Inc. (Montpelier, VT), and
results showed 1,066 mg of caffeoylquinic acids (CQA)
(specifically, 545 mg 3-CQA, 298 mg 4-CQA, 223 mg 5-
CQA), 474 mg caffeine, and 1,533 mg total phenolics per
300 ml Turkish boiled coffee. For the placebo coffee,
decaffeinated coffee beans were darkly roasted and finely
ground, and HPLC analysis showed that 30 grams in
300 ml boiled water (Turkish method as described)
provided 187 mg total CQA and 33 mg caffeine. The
CQA and placebo coffee grounds were packaged in
coded coffee bags, with the double blind code held until
the study was completed.
Plasma Caffeine Analysis
Plasma caffeine concentration was analyzed by aWaters
Acquity UPLC-Quattro Premier XE Mass Spectrometry
(Waters Corp., Milford, MA). Chromatographic separa-
tion of caffeine and the internal standard caffeine-d9 was
performed on a UPLC BEH C18 1.7 μm analytical
column (2.1 × 100 mm, Waters Corp., Milford, MA)
with a gradient elution using mobile phase A water and
mobile phase B acetonitrile, both containing 0.1% for-
mic acid. The separation was achieved by the following
gradients: 0–0.5 min (5% B), 0.5–2 min (5–80% B), 2–
2.1 min (80–100% B), 2.1–3.5 min (100% B), 3.5–
3.6 min (100–5% B), and 3.6–4 min (5% B). The flow
rate was 0.4 ml/min. Detection was performed using a
Waters Quattro Premier XE mass spectrometer that was
operated in positive ion mode with electrospray ioniza-
tion. The analyses were performed in the multiple reac-
tion monitoring (MRM) mode (caffeine 195 > 138 and
caffeine-d9 204 > 144). Instrument control and data
acquisition was performed using Masslynx software
package (Waters Corp., Milford, MA). The optimized
parameter settings were as follows: capillary 3 KV,
sampling cone 35 V, extraction cone 4V, source tem-
perature 120 °C, desolvation temperature 350 °C, des-
olvation gas flow 800 L/Hr.
Sample preparation was performed by protein pre-
cipitation with methanol. Fifty microliter aliquots of
plasma samples were transferred to 2 mL microcentri-
fuge tubes. 200 μL of methanol containing 40 ng/mL of
internal standard caffeine-d9 was added to each tube.
Samples were vortexed for 5 minutes and then centri-
fuged at 12,000 g for 10 min at 4 °C. The supernatant of
each tube was transferred to an autosampler vial for
LC-MS analysis.
Plasma FRAP Analysis
Total plasma antioxidant potential/capacity was deter-
mined by the ferric reducing ability of plasma (FRAP)
assay as previously described (Benzie & Strain, 1996).
This assay utilizes water-soluble antioxidants in the plasma
to reduce ferric iron to the ferrous form identifiable at
593 nm. Samples and standards were expressed as ascor-
bate equivalents based on an ascorbate standard curve. The
intra-assay coefficient of variation (CV) for FRAP
was 2.6%.
Plasma 9+ 13-HODE Analysis
Nine- and 13-hydroxy-octadecadienoic acids (9-HODE
and 13-HODE) were measured as previously described
(Nieman et al., 2014). Briefly, 10 μL of 500 ng/mL
9-HODE-d4 and 10 μL of 50 mM BHT were added to
200 μL of plasma sample. Then 1.0 mL (10% v/v acetic
acid in water)/2-propanol/hexane (2/20/30, v/v/v) and
2.0 mL hexane were used for extraction. After centrifuga-
tion, the upper layer was removed, dried and reconstituted
with 100 μL of 85% methanol in water (v/v, containing
0.1% acetic acid) for LC–MS analysis. Chromatographic
separation of 9-HODE and 13-HODE was achieved using
an UPLC system (Acquity UPLC, Waters, Milford, MA)
equipped withWaters BEH C18 1.7 μm analytical column
(2.1 × 100 mm). The mobile phases consisted of (A) 0.2%
acetic acid in water and (B) 0.2% acetic acid in acetonitrile.
The gradient used was: 0–0.5 min (80% B), 0.5–3 min
(80–100% B), 3–6 min (100% B), 6–6.1 min (100–80%
B), 6.1–7 min (80% B). For detection of 9-HODE and 13-
HODE, the UPLC system was coupled with Quattro
Premier XE MS (Waters, Milford, MA) and the system
was operated in electrospray ionization (ESI) negative
mode. The multiple reaction monitoring (MRM) was
performed with optimized transitions (295 > 171 for 9-
HODE; 295 > 195 for 13-HODE; and 299 > 172 for 9-
HODE-d4). All peaks were integrated using TargetLynx
Application Manager (Waters, Milford, MA), and the
peaks were quantified using calibration curves of peak
areas of native compounds divided by the internal standard
peak area.
Plasma IL-6 Analysis
Total plasma concentration of IL-6 was determined using
an electrochemiluminescence based solid-phase sandwich
immunoassay (Meso Scale Discovery, Gaithersburg, MD,
USA). All samples and provided standards were analyzed
in duplicate, and the inter-assay CV was 4.5%, with the
intra-assay CV ranging from 4 to 6%. Preexercise and
postexercise samples for the cytokines were analyzed on
the same assay plate to decrease inter-kit assay variability.
Profile of Mood States
An abbreviated 40-item version of the Profile of Mood
States was administered prior to and after the 2-week
coffee/placebo supplementation period, 30 minutes after
ingesting 1 cup of coffee/placebo (before the exercise
bout), and immediately following the 50-km cycling time
trial (Grove & Prapavessis, 1992). Since short-term
effects on mood were being measured, the “right now”
response was employed. All responses were based on a
five-point scale anchored by “not at all” (score of 0) and
“extremely” (score of 4). Scores for the seven subscales
were calculated by summing the numerical ratings for
items that contributed to each subscale, with the total
mood disturbance (TMD) calculated by summing the
totals for the negative subscales (tension, depression,
anger, fatigue, confusion) and then subtracting the total
for the positive subscales (vigor, esteem-related affect),
and adding 100 to eliminate negative scores.
Statistical Analysis
Data are presented as mean ± SE. Our power analysis
showed that at an effect size of 0.7 and alpha of
0.05, N = 15 in a randomized, crossover clinical trial
group design will provide a power of 0.90 for plasma
IL-6 (a variable for which sufficient data are available).
Subject characteristics were compared between
genders using independent t-tests, and performance
data were compared between CQA coffee and placebo
groups using dependent t-tests. All other data were
analyzed using a 2 (CQA coffee, placebo trials) × 3 or
4 (time points) repeated measures ANOVA, within
subjects’ approach. When interaction effects were sig-
nificant (p ≤ .05), changes from prestudy values within
trials were compared between trials using dependent
t-tests.
Results
Characteristics for the male (n = 10) and female (n = 5)
study participants are compared in Table 1. Age, body
mass index (BMI), and training distance were compara-
ble between gender groups, with maximum cycling
power (watts) and ventilation (L/min) higher in the
males compared to females. No differences were found
between male and female cyclists when comparing the
contrast in 50-km trial time performances between cof-
fee and placebo trials (gender difference, p = .19). Addi-
tionally, no significant between-subjects gender effects
were found using the GLMmodel for repeated measures
for TMD (p = .56), plasma caffeine (p = .14), plasma
IL-6 (p = .10), and HODEs (p = .99), and supports simi-
lar findings in our lab from a metabolomics-based study
(Nieman et al., 2013). Thus gender groups were com-
bined for all data analyses.
The performance measures for the coffee and pla-
cebo 50-km cycling time trials are summarized in
Table 2. Performance time, and absolute and relative
power and oxygen consumption did not differ between
the coffee and placebo trials. Average heart rate and
ventilation were higher with coffee compared to placebo,
especially at the 30-minute time point during the 50-km
cycling trials. The rating of perceived exertion (RPE)
tended to be lower at the 30-minute time point in the
coffee compared to placebo trial.
Three-day food records did not show any significant
differences inmacro- andmicro-nutrient intake during the
3-day period prior to the 50-km cycling time trials under
coffee and placebo conditions (data not shown). Energy
intakes were 8.29–0.76 MJ/day and 8.64–0.54 MJ/day,
with carbohydrate representing 45.7–3.1% and 47.0–
2.2%, protein 19.0–0.9% and 16.9–0.9%, and fat
35.1–2.9% and 36.3–1.5% of total energy for the coffee
and placebo trials, respectively (all p > .05). Caffeine
intake (irrespective of the coffee supplement) averaged
28.3–13.7 mg/day and 22.7–11.6 mg/day for the coffee
and placebo trials, respectively (p = .39). Total flavo-
noid intake (irrespective of the coffee supplement)
averaged 130–70.0 mg/day and 135–77.6 mg/day for
the coffee and placebo trials, respectively (p = .64).
Table 2 Performance Measurements During the Coffee and Placebo 50-Km Cycling Time Trials
(M ± SE)
Variable Coffee Placebo p-value
Time to complete 50-km cycling (minutes) 98.8 ± 3.2 99.2 ± 3.5 .71
Average power (watts) 169 ± 13.3 171 ± 13.3 .60
% maximal watts 67.2 ± 2.1 68.1 ± 2.3 .58
Average oxygen consumption (ml/min) 2533 ± 123 2516 ± 118 .80
% VO2max 76.9 ± 1.9 77.5 ± 2.1 .74
Average heart rate, 50-km (beats/min) 154 ± 3.9 150 ± 4.0 .003
30 minutes 156 ± 4.2 148 ± 4.3 <.001
60 minutes 154 ± 4.0 151 ± 4.0 .16
% maximal heart rate, 50-km 90.2 ± 1.6 87.5 ± 1.7 .004
Average ventilation, 50-km (L/min) 70.2 ± 2.9 65.0 ± 2.9 .07
30 minutes 74.3 ± 3.3 64.9 ± 3.4 .01
60 minutes 67.3 ± 3.3 65.8 ± 2.5 .60
Average respiratory rate, 50-km (breaths/min) 36.6 ± 2.1 35.5 ± 2.1 .45
30 minutes 36.2 ± 2.2 33.6 ± 2.3 .16
60 minutes 36.0 ± 2.2 36.3 ± 2.1 .88
Average respiratory exchange ratio, 50-km 0.84 ± 0.01 0.84 ± 0.01 .71
30 minutes 0.87 ± 0.01 0.85 ± 0.01 .15
60 minutes 0.83 ± 0.01 0.84 ± 0.01 .10
Average rating of perceived exertion, 50-km 13.0 ± 0.4 13.3 ± 0.4 .44
30 minutes 12.1 ± 0.5 12.9 ± 0.4 .06
60 minutes 13.5 ± 0.5 13.4 ± 0.5 .73
Table 1 Subject Characteristics (M ± SE)
Variable Males (n= 10) Females (n= 5) p-value
Age (years) 36.1 ± 3.3 40.0 ± 4.5 .51
Height (m) 1.79 ± 0.01 1.67 ± 0.02 .001
Weight (kg) 77.1 ± 2.1 63.4 ± 4.1 .01
Body mass index (kg/m2) 24.2 ± 0.7 22.6 ± 0.9 .20
Body fat (%) 15.3 ± 2.0 24.6 ± 3.0 .02
VO2max (ml · kg
−1 · min−1) 48.2 ± 2.3 40.4 ± 2.9 .06
Maximum power (watts) 280 ± 8.2 184 ± 13.0 <.001
Maximum heart rate (beats/min) 174 ± 4.6 167 ± 6.4 .46
Maximum ventilation (L/min) 139 ± 7.3 91.7 ± 4.5 .001
Maximum respiratory exchange ratio 1.17 ± 0.02 1.13 ± 0.04 .39
Maximum respiratory rate (breaths/min) 53.0 ± 3.4 44.4 ± 3.0 .12
Training distance (km/wk) 120 ± 25.2 98.2 ± 34.6 .62
Plasma caffeine was significantly higher in the
coffee compared to placebo condition after 2-weeks
ingestion and immediately postexercise (interaction
effect, p < .001) (Figure 1). TMD scores were lower
in the coffee compared to placebo condition (interaction
effect, p = .04), but contrasts did not differ significantly
at any particular time point (Figure 2). The pattern of
change in plasma FRAP between coffee and placebo
conditions differed significantly (interaction effect,
p = .01), especially immediately after the 50-km cycling
trials (Figure 3). No differences between coffee and
placebo trials were found for postexercise increases in
plasma IL-6 (interaction effect, p = .74) and plasma
HODEs (p = .99; Figures 4 and 5).
Discussion
This study utilized a randomized crossover design,
and showed that 2-weeks ingestion of high CQA
(1,066 mg/day CQA) versus placebo (187 mg/day
CQA) coffee prepared using the Turkish method did
not alter increases in inflammation and oxidative stress
after participating in a 50-km cycling time trial. Inges-
tion of one cup CQA coffee (474 mg caffeine) versus
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Figure 1— Plasma caffeine in CQA coffee and placebo trials (interaction effect, p < .001). P-values above bars represent contrast in
change from prestudy between trials.
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Figure 2 — Total mood disturbance (TMD) scores in CQA coffee and placebo trials (interaction effect, p = .04).
placebo (33 mg caffeine) 30 minutes prior to exercise
was associated with significant trial differences for
plasma caffeine (901% increase postexercise) and
FRAP, and improved mood state, but no difference in
50-km cycling time performance or power.
The 50-km cycling bout induced significant in-
creases in plasma IL-6 (650%) and 9 + 13 HODEs
(94%). Postexercise plasma IL-6 is an indicator of
inflammation, with highest levels seen after prolonged
and intensive endurance exercise (Nieman et al., 2014).
Linoleic acid is the direct precursor to the stable oxidized
metabolites 9 + 13 HODEs that function as biomarkers
for both oxidative stress and inflammation (Nieman
et al., 2014). 9 + 13 HODEs are secreted by a variety
of cells including macrophages, endothelial cells, plate-
lets, and smooth muscle cells, and exert biological and
signaling activities as proliferator-activated receptor
(PPAR) and G protein coupled receptor 132 (G2A)
ligands (Nieman et al., 2014). High versus low CQA
intake for two weeks was associated with higher FRAP
as reported by others (Agudelo-Ochoa et al., 2016;
Moura-Nunes et al., 2009; Natella et al., 2002), but
did not lower postexercise plasma levels of IL-6 and
9 + 13 HODEs. Several explanations are possible,
including the dosing regimen (e.g., duration, daily
dose and timing), and issues related to CQA
biotransformation.
Cell culture studies indicate that CQAs (in particu-
lar, 5-CQA) exert antioxidant and anti-inflammatory
influences through multiple pathways, and downregulate
pro-inflammatory cytokines through modulation of key
transcription factors (Liang & Kitts, 2014, 2015). How-
ever, a relatively low percentage of CQAs are absorbed
in the small intestine, and these metabolites appear in
low concentrations in the plasma 1- to 2-hours post-
ingestion in conjugated form (i.e., linked to sulfate,
methyl, and glucuronide molecules) (Del Rio et al.,
2010). There is a growing realization that the colon
plays a major role in CQA metabolism. Most CQAs
pass through the small intestine unabsorbed, and then are
extensively transformed by intestinal microbes. Substan-
tial quantities of these colonic catabolites can be ab-
sorbed into the portal vein and pass through the liver into
the circulation prior to excretion in the urine. Most CQA
metabolites formed by intestinal transformation also
become methylated, sulfated, or glucuronated (Lang
et al., 2013; Stalmach et al., 2010). Some of these
compounds have been studied and found to exert anti-
inflammatory and antioxidant effects, but results from
human intervention trials are unclear (Martini et al.,
2016). More information is needed to understand under-
lying mechanisms, biochemical pathways, optimal dos-
ing regimens, appropriate biomarkers, and reasons for
the large variation between study participants (Lang
et al., 2013). Martini et al. (2016) reviewed human
coffee intervention studies and concluded that long-
term exposure to coffee and its bioactive, metabolically
transformed metabolites may be needed before measur-
able influences are experienced. In support, two epide-
miological studies reported an inverse, modest
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Figure 3 — Plasma FRAP in CQA coffee and placebo trials (interaction effect, p = .01). P-values above bars represent contrast in
change from prestudy between trials.
association between habitual coffee consumption and
various measures of inflammation including CRP, IL-6,
soluble tumor necrosis factor-receptor 2, E-selectin, and
soluble vascular adhesion molecule-1 (Kempf et al.,
2010; Lopez-Garcia et al., 2006).
In this study, 50-km cycling performance and power
did not differ between coffee and placebo trials, with
coffee ingestion associated with significantly increased
heart rate and ventilation at the 30-minute time point,
and reduced RPE (p = .06). Most performance studies
have utilized anhydrous caffeine, and although results
are not entirely consistent, reviewers have concluded
that ingestion of 3–6 mg/kg caffeine is associated with
reduced RPE during exercise and improved time-trial
performance (Doherty & Smith, 2005; Goldstein et al.,
2010; McLellan et al., 2016). Fewer exercise perfor-
mance studies have been published with caffeinated
coffee, and results are mixed and in general less impres-
sive than when anhydrous caffeine is consumed
(Goldstein et al., 2010). One review showed that five
of nine studies observed significant improvements in
endurance performance, and three of six showed reduced
RPE with caffeinated coffee ingestion (Higgins et al.,
2016). Comparisons between studies are difficult due to
varying research designs, the lack of randomized pla-
cebo control trials, insufficient information regarding the
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Figure 4 — Plasma IL-6 in CQA coffee and placebo trials (interaction effect, p = .74).
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Figure 5 — Plasma 9 + 13 HODEs in CQA coffee and placebo trials (interaction effect, p = .99).
caffeine and CQA concentrations in the coffee doses,
and the use of time-to-exhaustion exercise challenges
instead of the preferred exercise time trials (Goldstein
et al., 2010; Higgins et al., 2016). Although not a
consistent finding, other investigators have reported
higher exercise heart rates during caffeine compared
to placebo trials (Hunter et al., 2002), and this may
be due in part to increased release of the neurotransmitter
noradrenaline that has been linked to intake of high
caffeine doses ((McLellan et al., 2016).
Following ingestion, caffeine is rapidly absorbed,
with plasma levels rising to peak levels within one hour
(Blanchard & Sawers, 1983). Our cyclists consumed one
cup of coffee (474 mg caffeine) 30 minutes prior to the
50-km cycling time trial (99-minute average completion
time), ensuring that plasma caffeine levels peaked during
exercise. Caffeine plasma half-lives vary from 2.7 to
9.9 h, and behavioral effects are in part due to antago-
nism of A1 and A2a adenosine receptors in the CNS and
interactions with dopamine receptors, and increased
release of a variety of neurotransmitters including dopa-
mine and serotonin (McLellan et al., 2016). Most studies
support that ingestion of moderate caffeine doses im-
proves vigilance, learning, and mood (Childs & de Wit,
2008; McLellan et al., 2016). One meta-analysis of 21
studies concluded that caffeine ingestion reduced RPE
during exercise by 5.6%, with an equivalent RPE effect
size of −0.47 (Doherty & Smith, 2005), and is consistent
with our data showing a reduction in RPE at 30 minutes
during the 50-km cycling time trial. Our data also
support a significant trial difference for mood state as
reported in other similar studies using both anhydrous
caffeine and caffeinated coffee (Church et al., 2015;
McLellan et al., 2016). Limited data suggest that CQA
ingestion has a modest, positive effect on some aspects
of mood state, but this has not been studied within
an exercise context and potential underlying mechan-
isms have not been adequately explored (Camfield
et al., 2013).
In summary, 2-weeks ingestion of coffee versus
placebo prepared using the Turkish method and supply-
ing 1,066 mg/day CQA and 474 mg/day caffeine
increased plasma antioxidant capacity but did not offset
increases in IL-6 and 9 + 13 HODEs following a 50-km
cycling time trial. Plasma caffeine was higher and TMD
scores lower with CQA coffee versus placebo, but 50-
km cycling time performance and power did not differ
between trials. These data do not support the strategy of
ingesting coffee highly concentrated with chlorogenic
acids and caffeine for two weeks prior to and the
morning of a 50-km cycling time trial in lessening
postexercise inflammation or oxidative stress.
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